Biotech Showcase
Biotech Showcase is back in person!
January 9–11, 2023 | San Francisco, CAJanuary 18–19, 2023 | Virtual

Camille Samuels
Partner at Venrock

Profile

Camille (Cami) Samuels focuses on healthcare with an emphasis on biotech, medical devices, and consumer health. She currently serves on the board of Cavalry, Iris, Mahzi, Ocelot, Unity (UBX), and XCaliber. She previously served the boards of several exited Venrock portfolio companies, including Corvidia (sold to Novo), RegenXBio (RGNX), and Spirox (now owned by Stryker). Prior to Venrock, Cami was a Managing Director at Versant Ventures where she served on the board (or as a board observer) at many companies including Genomic Health (GHDX/sold to Exact), Jazz (JAZZ), Kythera (KYTH/sold to Allergan), Novacardia (sold to Merck), and ParAllele (sold to Affymetrix). During her early career, Cami worked in corporate development at Genzyme, Millennium Predictive Medicine, and Tularik, and she was a management consultant at LEK Consulting. Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School (HBS), where she graduated as a Baker Scholar. She is a Henry Crown Fellow, serves on the Investment Advisory Committee of Mission BioCapital (MBC), and serves on the HBS Global Advisory Board.

Agenda Sessions

  • Finance: The 2022 Outlook

    12:00